Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „dupilumab“
Suchtreffer
Begriffe & Kennungen
Dupixent · 4.8 · Children 6 to 11 years of age The safety of dupilumab was assessed in a study of 367 patients 6 to 11 years of
Eintrag öffnenDupixent · 4.8 · Eczema herpeticum Eczema herpeticum was reported in < 1 % of the dupilumab groups and in < 1 % of the placebo
Eintrag öffnenDupixent · 4.8 · Eosinophilia Dupilumab-treated patients had a greater mean initial increase from baseline in eosinophil count
Eintrag öffnenDupixent · 4.8 · Eosinophilia Dupilumab-treated patients had a greater mean initial increase from baseline in eosinophil count
Eintrag öffnenDupixent · 4.8 · Immunogenicity As with all therapeutic proteins, there is a potential for immunogenicity with dupilumab.
Eintrag öffnenDupixent · 4.8 · Immunogenicity As with all therapeutic proteins, there is a potential for immunogenicity with dupilumab.
Eintrag öffnenDupixent · 4.8 · Less than 1 % of patients who received dupilumab at approved dosing regimens exhibited high titer ADA response
Eintrag öffnenDupixent · 4.8 · No increase was observed in the overall incidence of infections with dupilumab compared to placebo in the safe
Eintrag öffnenDupixent · 4.8 · No increase was observed in the overall incidence of infections with dupilumab compared to placebo in the safe
Eintrag öffnenDupixent · 4.8 · No increase was observed in the overall incidence of infections with dupilumab compared to placebo in the safe
Eintrag öffnenDupixent · 4.8 · No increase was observed in the overall incidence of infections with dupilumab compared to placebo in the safe
Eintrag öffnenDupixent · 4.8 · No increase was observed in the overall incidence of infections with dupilumab compared to placebo in the safe
Eintrag öffnenDupixent · 4.8 · No increase was observed in the overall incidence of infections with dupilumab compared to placebo in the safe
Eintrag öffnenDupixent · 4.8 · No increase was observed in the overall incidence of infections with dupilumab compared to placebo in the safe
Eintrag öffnenDupixent · 4.8 · The dupilumab safety data presented in Table 8 were predominantly derived from 12 randomised, placebo-controll
Eintrag öffnenDupixent · 4.8 · The dupilumab safety data presented in Table 8 were predominantly derived from 12 randomised, placebo-controll
Eintrag öffnenDupixent · 4.8 · The long-term safety of dupilumab was assessed in 89 adolescent patients who were enrolled in an open-label ex
Eintrag öffnenDupixent · 4.8 · The long-term safety of dupilumab was assessed in 89 adolescent patients who were enrolled in an open-label ex
Eintrag öffnenDupixent · 4.8 · The long-term safety of dupilumab was assessed in an open-label extension study (EXCURSION) in children 6 to 1
Eintrag öffnenDupixent · 4.8 · The overall incidence of infections was numerically higher with dupilumab (32.0%) compared to placebo (24.8%)
Eintrag öffnen